Sterling Capital Management’s First Tracks Biotherapeutics TRAX Stock Holding History

Sterling Capital Management’s Portfolio TRAX Stock Details TRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.96K	Buy	+197	New	+$3.68K	﹤0.01%	2743

Other funds holding TRAX

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.67B AUM 89% 1-Year Est. Return

Mirae Asset Global Investments

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

EverSource Wealth Advisors Birmingham, Alabama $2.97B AUM 28.74% 1-Year Est. Return

Sterling Capital Management's TRAX Position: Q2 2026 in Review

Sterling Capital Management opened a new position in First Tracks Biotherapeutics (TRAX) in Q2 2026: 197 shares worth $3.96K. The stake represents ﹤0.01% of the portfolio and ranks #2743 among its holdings.

19 funds tracked by Wall St. Rank hold TRAX as of Q2 2026.

Sterling Capital Management held 197 shares of First Tracks Biotherapeutics worth $3.96K as of Q2 2026.
First Tracks Biotherapeutics was a new Sterling Capital Management position in Q2 2026.
First Tracks Biotherapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2743 holding.
19 funds tracked by Wall St. Rank held First Tracks Biotherapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.